FDA OKs Invitrogen genetic test for breast cancer

	Tweet

The U.S. Food and Drug Administration on Tuesday approved Invitrogen Corp’s genetic test for determining whether patients with breast cancer are good candidates for treatment with the drug Herceptin.

Invitrogen’s test—the SPOT-Light HER2 CISH kit—measures the number of copies of the HER2 gene in tumor tissue. Patients who over-produce the HER2 protein are typically treated with the drug Herceptin, which is made by Genentech.

“When used with other clinical information and laboratory tests, this test can provide health care professionals with additional insight on treatment decisions for patients with breast cancer,” Dr. Daniel Schultz, director of the FDA’s Center for Devices and Radiological Health, said in a statement.

The Invitrogen test counts the number of HER2 genes in a small sample of removed tumor, the FDA said. The removed piece is stained with a chemical that causes any HER2 genes to change color. This color change can be visualized under a standard microscope, eliminating the need for the more expensive and complex fluorescent microscopes required to read assays already on the market, the agency said.

Unlike existing tests, the Invitrogen test allows labs to store the tissue for future reference, the FDA said.

The drug Herceptin targets HER2 protein production and attempts to stop the growth of the HER2 cancer cells.

The FDA said it based its approval of the Invitrogen test on a study using tumor samples from patients with breast cancer in the United States and Finland. The data confirmed the test was effective in determining how many HER2 genes were present, it said.

Invitrogen, based in Carlsbad, Calif, provides technologies for disease research and drug discovery. The company had revenue of $1.3 billion in 2007.

WASHINGTON (Reuters)

RELATED STORIES:
Breast Cancer Surgery Preserves Artery for Future Heart Surgery   Many U.S. women do not get recommended mammograms   Breast Reconstruction’s Modern Look   Nicotine in cigarettes linked to breast cancer for the first time   Integrating genetic information with breast cancer risk factors may help refine prognosis   Manchester researchers announce new methods of beating breast cancer   Understanding individual genetic variation can help predict chemotherapy side effects   Scientists Break Genetic Code for Estrogen-Positive Breast Cancer   Racial differences in severity of breast cancer presentation confirmed   Cancer Scientists Discover New Way Breast Cancer Cells Adapt to Environmental Stress   One-step Breast Cancer Treatment Combines Radiation, Surgery   New screening technique could provide more reliable breast cancer detection   Large study documents how p53 mutations link to high-grade breast cancer, poor outcomes   Long-term tamoxifen use increases risk of an aggressive, hard to treat type of second breast cancer   Cadmium linked to breast cancer   Research aims to starve breast cancer cells   What Breast Cancer Patients Don’t Know About Mastectomy Options Can Cause Lifelong Disfigurement   Racial Disparities Exist in Radiation Therapy Rates for Early Stage Breast Cancer   BRCA Mutations Among Asian-American Women May be More Common Than Predicted   Breast cancer rates fell with hormone therapy drop   New Technique Detects Early Metastasis of Breast Cancer   Age 50 as Mammography Screening Threshold Proven Unfounded

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]